Interestingly, in a randomised, phase II clinical trial, the combination of gemcitabine with the ATRi berzosertib was more efficacious than gemcitabine monotherapy treatment, in high-grade serous ovarian cancer (HGSOC) patients.48 Similarly, the combination of gemcitabine (and radiation) with WEE1i in pancreatic cancer showed efficacy in a recent phase I clinical trial.49 Future analysis of clinical cohorts will enable to ascertain whether the efficacy of the combinations may be attributed to low or absent SLFN11 protein in the tumour cells of these patients. The gene discussed is SLFN11; the disease is pancreatic neoplasm.